Vericel Co. (NASDAQ:VCEL) Insider Jonathan Siegal Sells 3,908 Shares

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total transaction of $242,256.92. Following the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Vericel Stock Up 0.5 %

VCEL traded up $0.27 during midday trading on Thursday, hitting $59.25. 269,823 shares of the company were exchanged, compared to its average volume of 437,838. The firm has a market capitalization of $2.92 billion, a P/E ratio of 987.66 and a beta of 1.72. The firm’s 50 day moving average price is $57.66 and its 200-day moving average price is $50.75. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $61.99.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. On average, sell-side analysts predict that Vericel Co. will post 0.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vericel

Institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC lifted its position in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares during the period. Farther Finance Advisors LLC increased its position in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Vericel during the third quarter worth approximately $92,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Vericel by 826.6% in the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,240 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a report on Tuesday, November 19th. Truist Financial increased their price target on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.